Circadian Variation of Stent Thrombosis and the Effect of More Robust Platelet Inhibition

Background: The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplatelet therapy with prasugrel (vs clopidogrel) can attenuate a morning excess. Methods and Materials: Patients from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial (N = 13 608) with adjudicated ST classified per the Academic Research Consortium definitions of definite (N = 135) and probable (N = 27) were grouped into prespecified 8-hour intervals by time of onset: early (6 am-2 pm), late-day (2 pm-10 pm), and overnight (10 pm-6 am). We compared the rates per 1000 patients of ST across time intervals and stratified by treatment and stent type. Results: A diurnal variation in definite/probable ST was observed with rates of 6.5, 3.7, and 2.1 for early, late-day, and overnight intervals, respectively (P < .001), per 1000 patients treated. A sensitivity analysis excluding periprocedural acute-ST (<24 hours after index percutaneous coronary intervention [PCI]) resulted in similar findings (5.2, 2.5, and 1.8 per 1000, P < .001). The circadian variation in ST was observed in patients on clopidogrel (9.7, 4.8, and 3.1 per 1000, P < .001) with the highest rate of ST early in the day. Patients on prasugrel also demonstrated a circadian variation with particularly low rates of overnight ST (3.4, 3.0, and 1.1 per 1000, P = .020). Conclusions: In TRITON-TIMI 38 trial, the timing of ST exhibited a significant diurnal variation similar to that seen with onset of other acute coronary syndromes. ST occurred less frequently among patients randomized to prasugrel compared to clopidogrel with the greatest absolute reduction (6.2 per 1000 patients) in events earlier in the day when platelet activity is known to be highest.

[1]  E. Antman,et al.  Relation Between Time of Symptom Onset of ST‐Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry , 2013, Clinical cardiology.

[2]  A. Ferro,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications , 2012, Clinical Pharmacokinetics.

[3]  E. Antman,et al.  Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction , 2012, Chronobiology international.

[4]  G. Lemesle,et al.  Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  D. Holmes,et al.  Circadian variation in coronary stent thrombosis. , 2011, JACC. Cardiovascular interventions.

[6]  J. Lindbäck,et al.  Stent Thrombosis in Sweden: A Report From the Swedish Coronary Angiography and Angioplasty Registry , 2009, Circulation. Cardiovascular interventions.

[7]  R. Starzyk,et al.  Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. , 2009, Circulation. Cardiovascular interventions.

[8]  John Bresnahan,et al.  Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.

[9]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[10]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[11]  K. Winters,et al.  A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.

[12]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[13]  S. Yano,et al.  Circadian variation in symptomatic subacute stent thrombosis after bare metal coronary stent implantation. , 2006, The American journal of cardiology.

[14]  B. Gersh.  Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents , 2006 .

[15]  I. Iakovou,et al.  Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era. , 2005, The American journal of cardiology.

[16]  C. Macaya,et al.  Findings of intravascular ultrasound during acute stent thrombosis , 2004, Heart.

[17]  A. Forer,et al.  From megakaryocytes to platelets: platelet morphogenesis takes place in the bloodstream , 1998, European journal of haematology. Supplementum.

[18]  J. Loscalzo,et al.  Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. , 1992, The American journal of cardiology.

[19]  J. Manson,et al.  Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. , 1990, Circulation.

[20]  S. Willich,et al.  Increased morning incidence of myocardial infarction in the ISAM Study: absence with prior beta-adrenergic blockade. ISAM Study Group. , 1989, Circulation.

[21]  C A Czeisler,et al.  Morning increase in platelet aggregability. Association with assumption of the upright posture. , 1988, Circulation.

[22]  E. Braunwald,et al.  Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.